AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25597699
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng (1200 mg)
Trial: 21832958
Drug: CNI standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI standard therapy
Trial: 17907113
Drug: Pioglitazone (30-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30-45 mg/day)
Trial: 15889234
Drug: Gliclazide (80-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (80-320 mg/day)
Trial: 9530343
Drug: Aphidicolin (APC)
RxNorm normalized name: Recombinant human activated protein C (rH-APC)
DrugBank: Aphidicolin (DB17742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphidicolin (APC) treatment in PHA-stimulated lymphocyte cultures
Trial: 9530343
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no APC treatment)
Trial: 2587826
Drug: Concurrent instruction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent instruction (two sessions per day, random presentation of two words)
Trial: 26328624
Drug: OM3‐CA 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3‐CA 4 g/d
Trial: 26328624
Drug: Control (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (olive oil, OO) 4 g/d
Trial: 15074449
Drug: Cessation services
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cessation services received by smokers with COPD (advised to quit, prescribed nicotine patches, referred to a smoking cessation program)
Trial: 8874076
Drug: polyI:polyC12U (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polyI:polyC12U (400 or 700 mg) with zidovudine
Trial: 1502478
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg twice daily for 6 months
Trial: 1502478
Drug: Prior omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior omeprazole therapy
Trial: 30962264
Drug: Dexmedetomidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 μg/(kg · min) for 10 min before surgery
Trial: 27312678
Drug: Remote limb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote limb ischemic conditioning (RLIC) once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 200 mm Hg, followed by 5 min of reperfusion.
Trial: 27312678
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 60 mm Hg, followed by 5 min of reperfusion.
Trial: 20364590
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (120 mg/d for 8 weeks)
Trial: 19091199
Drug: Pio+Met (pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pio+Met (pioglitazone plus metformin)
Trial: 10831027
Drug: pindolol 2.5
RxNorm normalized name: pindolol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol 2.5 mg three times daily
Trial: 10831027
Drug: placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo three times daily
Trial: 9091392
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) 5.9 g/d
Trial: 9091392
Drug: Control (stools
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (stools collected at least 24 h after the last fecal excretion of PEG)
Trial: 12682802
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg four times daily for 7 days
Trial: 26636422
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of febuxostat 80 mg
Trial: 26636422
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of febuxostat 40 mg
Trial: 26636422
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of febuxostat 80 mg
Trial: 29606665
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) monotherapy
Trial: 27175292
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) + Methotrexate (MTX) combination therapy
Trial: 21997881
Drug: Flaxseed pillow
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed pillow treatment
Trial: 14614003
Drug: Intraperitoneal (i.p.)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (i.p.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to subcutaneous (s.c.) at 4 weeks.
Trial: 14614003
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to intraperitoneal (i.p.) at 4 weeks.
Trial: 14614003
Drug: Both i.p.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both i.p. and s.c. administration of Flt3-L.
Trial: 6827423
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (albuterol)
Trial: 7574130
Drug: Subcutaneous epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous epinephrine
Trial: 26471212
Drug: Dextromethorphan/quinidine (DM/Q)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan/quinidine (DM/Q) 20/10 mg twice daily
Trial: 22192488
Drug: Twice-yearly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-yearly treatment
Trial: 11881868
Drug: Peribulbar block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar block with 5 ml of 1:1 mixture of 0.5% plain bupivacaine and 2% lignocaine supplemented with hyaluronidase 300 i.u. ml(‐1)
Trial: 11881868
Drug: Deep topical
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep topical fornix nerve block anaesthesia (DTFNBA) with placement of a sponge soaked in 0.5% bupivacaine deep into the conjunctival fornices for 15 min
Trial: 10211536
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg (Control)
Trial: 10211536
Drug: Lovastatin 10
RxNorm normalized name: lovastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 10 mg
Trial: 2611069
Drug: Fluid preloading
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid preloading with 1 litre of crystalloid fluid given at a rate of 1000 ml in 15 min before spinal anaesthesia
Trial: 2611069
Drug: No preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preload group (1 ml min‐1 fluid rate)
Trial: 328335
Drug: Sexual steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual steroids (Estrovis 4000)
Trial: 30977980
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet administration
Trial: 26610558
Drug: TheaTrim (Purus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TheaTrim (Purus Labs; containing a branded form of theacrine (Teacrine™) and caffeine (150 mg))
Trial: 26610558
Drug: Caffeine only
RxNorm normalized name: Caffeine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine only (150 mg)
Trial: 10586394
Drug: Linezolid 375
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 375 mg
Trial: 7537913
Drug: Newer agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer agents (Paclitaxel, Docetaxel, Vinorelbine, Amonafide)
Trial: 7537913
Drug: Novel approaches
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel approaches (differentiating agents, anti-angiogenesis factors, antitumor antigen-based therapy, growth factor receptor/ligand therapy, gene therapy)
Trial: 2030804
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg o.d. (n = 62)
Trial: 2030804
Drug: Captopril/nifedipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril/nifedipine combination
Trial: 6786635
Drug: Fried karela
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fried karela fruits consumed as a daily supplement
Trial: 26842665
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein (WP) 24 g
Trial: 26842665
Drug: Maltodextrin (MD)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (MD) 24 g
Trial: 17435957
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk (72 mg isoflavones/day)
Trial: 17435957
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk and isoflavone supplement (70 mg isoflavones/day)
Trial: 17435957
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk and placebo supplement (control)
Trial: 11896339
Drug: IV fluid
RxNorm normalized name: IV fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluid replacement (500 mL of HES)
Trial: 8576296
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg intravenous 4‐trans‐hydroxyglibenclamide (M1)
Trial: 8576296
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg intravenous 3‐cis‐hydroxyglibenclamide (M2)
Trial: 8576296
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of intravenous and oral administration of glyburide
Trial: 2198414
Drug: Dapsone 100
RxNorm normalized name: dapsone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 100 mg daily, non-supervised for 3 years
Trial: 2198414
Drug: RMP 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP 900 mg supervised, once weekly, 8 doses
Trial: 2198414
Drug: RMP 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP 600 mg, once monthly, supervised, 6 doses with dapsone 100 mg daily unsupervised
Trial: 2198414
Drug: RMP 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP 600 mg together with dapsone 100 mg daily, supervised for 6 days
Trial: 30289444
Drug: Original-dose ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original-dose ring (VCV, 182 mg; MK-2048, 30 mg)
Trial: 28275807
Drug: Semiconductor laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semiconductor laser therapy combined with botulinum toxin A type injection (50 U injected into masseteric and temporal muscles, 5 injections at different sites on each side, treatment course of 2 weeks)
Trial: 22301766
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) and 2 g α-linolenic acid (ALA)
Trial: 15185464
Drug: Equivalence trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalence trials in cardiovascular medicine
Trial: 15185464
Drug: Non-inferiority trials
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-inferiority trials in cardiovascular medicine
Trial: 12006420
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg twice daily)
Trial: 2571469
Drug: Bethanechol, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol, 10 mg subcutaneously
Trial: 2571469
Drug: Midazolam, 5
RxNorm normalized name: Midazolam, 5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, 5 mg intramuscularly
Trial: 773581
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (DPH) 25 mg every 4 hr for four doses
Trial: 30859862
Drug: HMB-FA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-FA (3 g/day; n=14)
Trial: 30859862
Drug: HMB-Ca (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-Ca (3 g/day; n=15)
Trial: 30859862
Drug: Placebo (cornstarch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cornstarch, 3 g/day; n=15)
Trial: 21332331
Drug: Silymarin 140
RxNorm normalized name: silymarin 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140 mg 3 times daily
Trial: 16047465
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl 2.3 g/day
Trial: 16047465
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl 3.8 g/day
Trial: 12019592
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received a 30-minute feedback on physical capacity and individual exercise prescription and counseling)
Trial: 10155357
Drug: CFC preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC preparations
Trial: 10155357
Drug: Salbutamol and
RxNorm normalized name: salbutamol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol and CFC preparations
Trial: 1911606
Drug: Placebo sprays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sprays
Trial: 24364108
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group 2)
Trial: 12622760
Drug: 4.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g/day mesalazine
Trial: 12622760
Drug: 2.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day mesalazine
Trial: 10676721
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 microg/d) plus calcium carbonate (500 mg/d of elemental calcium)
Trial: 9345358
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy + Wertheim‐Meigs + radiotherapy
Trial: 27512927
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg daily for 6 months
Trial: 25203576
Drug: High-pitch ultra-low-dose
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-pitch ultra-low-dose CT
Trial: 19020244
Drug: Lower injection
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower injection rate protocol: 20 mL of gadopentetate dimeglumine at 2 mL/s, 8 mL of gadopentetate dimeglumine at 1 mL/s, and 20 mL of saline solution at 1 mL/s.
Trial: 19020244
Drug: Higher injection
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher injection rate protocol: 20 mL of gadopentetate dimeglumine at 1.2 mL/s, 8 mL of gadopentetate dimeglumine at 0.7 mL/s, and 20 mL of saline solution at 0.7 mL/s.
Trial: 16392777
Drug: Three-day treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day treatment with trimethoprim
Trial: 16392777
Drug: Five-day treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day treatment with trimethoprim
Trial: 3931596
Drug: 5% Albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Albumin added to potassium crystalloid solution
Trial: 3931596
Drug: Standard potassium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard potassium crystalloid solution
Trial: 27314118
Drug: Both EC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both EC and IC implants
Trial: 14727272
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% with a basal rate of 4 mL/h and a 6 mL patient-controlled bolus available each hour (4/6 group, n = 12)
Trial: 20675620
Drug: Testosterone supplementation
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone supplementation (100 mg intramuscular every 2 weeks for 26 weeks)
Trial: 12102473
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with cyclosporine (CSA) and methotrexate (MTX) plus prednisone (PDN) (group B)
Trial: 3040923
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy
Trial: 2737235
Drug: Neostigmine 0.5
RxNorm normalized name: neostigmine 0.5 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.5 mg s.c. followed by metoclopramide 10 mg i.v.
Trial: 2737235
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg i.v.
Trial: 2737235
Drug: Neostigmine 0.5
RxNorm normalized name: neostigmine 0.5 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.5 mg s.c.
Trial: 27203508
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (fluticasone furoate 100 μg and vilanterol 25 μg)
Trial: 30165984
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (100 μg)
Trial: 30165984
Drug: Vilanterol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol (25 μg)
Trial: 12581974
Drug: Glucocorticoid (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (20 mg/d for 10 d, gradually decreased afterwards) + vitamin B + coenzyme Q10
Trial: 24582567
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg resveratrol daily for 8 weeks
Trial: 20089104
Drug: FCH PETCT
RxNorm normalized name: piperazine
DrugBank: Piperazine (DB00592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FCH PETCT imaging at 15 min after injection
Trial: 20089104
Drug: FCH PETCT
RxNorm normalized name: piperazine
DrugBank: Piperazine (DB00592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FCH PETCT imaging at 60 min after injection
Trial: 18059587
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein plus carbohydrate beverage (10 g protein and 21 g fructose)
Trial: 18059587
Drug: Carbohydrate-only beverage
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-only beverage (21 g fructose and 10 g maltodextran)
Trial: 16525941
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Bisoprolol + Enalapril)
Trial: 793524
Drug: UV irradiation
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV irradiation with 1% CCT ointment
Trial: 793524
Drug: UV irradiation
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV irradiation with ointment
Trial: 793524
Drug: 1% CCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% CCT ointment and UV irradiation
Trial: 793524
Drug: High-concentration (6%)
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration (6%) tar ointment without UV irradiation
Trial: 28406788
Drug: Disease-modifying agents
RxNorm normalized name: LIPID MODIFYING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying agents (DMAs) with varying characteristics including dosage type, efficacy, relapse risk, and side effects.
Trial: 23994379
Drug: Schwarz measles
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz measles vaccine (SW)
Trial: 23994379
Drug: Edmonston-Zagreb measles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb measles vaccine (EZ)
Trial: 2877594
Drug: Succinylcholine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1.5 mg/kg)
Trial: 8436517
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rate 0.73 Gy.h‐1